Arch Biopartners, Inc.

Arch Cancer Therapeutics, Inc.

Uti Limited Partnership

Paul Kubes

Stephen Mark Robbins

Donna Lorraine Senger

Jennifer Joy Rahn

Daniel Abraham Muruve

Liane Babes

Saurav Roy Choudhury

Arthur Wing Sze Lau

Elizabeth M Long

Ela Kolaczkowska

Justin MacDonald

Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.

DPEP-1 binding compositions and methods of use

DPEP-1 binding agents and methods of use

Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.

Peptides that block leukocyte recruitment and methods of use

The present invention provides modified TLR2 ligands useful for modulating inflammatory responses. In particular, the ligands comprise (a) a fatty acid di- or tri-linoleate and (b) a GM1-binding peptide. The linoleate provides the anti-inflammatory function, while the GM1-binding peptide facilitates endocytosis.

Modified toll-like receptor 2 (TLR2) ligands as inhibitors of neutrophil recruitment

Growing community of inventors

Calgary, Canada

Paul Kubes